with OPEX of $25M I believe ist more like 32000 tests.
I completely agree regarding the potential for the company. The company have always suggested that they are re-writing the GOLD standard for bladder cancer. It’s non invasive and highly accurate.
I would suggest within the next 3 years there may be either a take over offer or listing on the US exchange.
However I still think a CR is coming.
I mentioned in earlier posts the following
Essentially I pick that there is 3 months before another credit raise.
If the LCD comes through PEB can recognise 3.6M USD in revenue. $5.6M NZD. That doubles Revenue for the FY!
in conjunction to that they can negotiate a payment for the previous tests completed. (17000 tests). This has been invoiced but not paid as there is no LCD. This is $20M USD worth of tests produced. I don’t for one minute believe that PEB will bet the full amount but it shows the potential.
This years test (revenue not recognised) plus back log is Almost $25M NZD.
- Forums
- NZX - By Stock
- PEB
- Ann: GENERAL: PEB: Kaiser Permanente Approves Commercial Use of Cxbladder
Ann: GENERAL: PEB: Kaiser Permanente Approves Commercial Use of Cxbladder, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add PEB (NZSX) to my watchlist
(20min delay)
|
|||||
Last
15.8¢ |
Change
0.003(1.94%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
15.6¢ | 16.4¢ | 15.6¢ | $35.83K | 223.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
0 | 12879 | 15.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.4¢ | 76943 | 0 |
Last trade - 11.00am 04/10/2024 (20 minute delay) ? |
Featured News
PEB (NZSX) Chart |